ARGX vs GILD
Argenx SE and Gilead Sciences, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | ARGX | GILD |
|---|---|---|
| Revenue | $4.2B | $29.4B |
| Net income | $1.3B | $8.5B |
| Gross margin | 89.1% | 78.8% |
| Net margin | 31.1% | 28.9% |
| Return on equity | 20.2% | 40.5% |
| Diluted EPS | $19.57 | $6.78 |
| Dividend / share | · | $3.16 |
| Payout ratio | · | 47.0% |
| Free cash flow | $679.0M | $9.5B |
| Equity | · | $22.7B |
| Net debt / equity | · | 0.77× |
| Current ratio | 5.23× | 1.55× |
| Revenue CAGR 5y | 151.5% | 3.6% |
| Profit CAGR 5y | · | 133.3% |
GILD bills 7.1× the revenue of ARGX, and ARGX keeps more of each dollar of revenue as profit (31.1% against 28.9%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | ARGX | GILD |
|---|---|---|
| FY2025 | $4.2B | $29.4B |
| FY2024 | $2.2B | $28.8B |
| FY2023 | $1.2B | $27.1B |
| FY2022 | $400.7M | $27.3B |
| FY2021 | $497.3M | $27.3B |
| FY2020 | $41.2M | $24.7B |
| FY2019 | $78.5M | $22.4B |
| FY2018 | · | $22.1B |
| FY2017 | · | $26.1B |
| FY2016 | · | $30.4B |
Bottom line
| Fiscal year | ARGX | GILD |
|---|---|---|
| FY2025 | $1.3B | $8.5B |
| FY2024 | $833.0M | $480.0M |
| FY2023 | $-295.1M | $5.7B |
| FY2022 | $-709.6M | $4.6B |
| FY2021 | $-408.3M | $6.2B |
| FY2020 | $-608.5M | $123.0M |
| FY2019 | $-181.2M | $5.4B |
| FY2018 | · | $5.5B |
| FY2017 | · | $4.6B |
| FY2016 | · | $13.5B |
7 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$25,291,684,000 | GILD |
| FY2024 | −$26,568,117,000 | GILD |
| FY2023 | −$25,925,217,000 | GILD |
| FY2022 | −$26,880,280,000 | GILD |
| FY2021 | −$26,807,723,000 | GILD |
| FY2020 | −$24,647,757,000 | GILD |
| FY2019 | −$22,370,538,000 | GILD |
GILD has reported the higher revenue in every one of these 7 fiscal years. The gap has widened since the earliest year compared.
7 of 19 comparable fiscal years — a year missing data on either side is not counted.
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +2.2 pp | ARGX |
| FY2024 | +36.4 pp | ARGX |
| FY2023 | −45.5 pp | GILD |
| FY2022 | −193.8 pp | GILD |
| FY2021 | −104.8 pp | GILD |
| FY2019 | −254.8 pp | GILD |
| FY2018 | −334.9 pp | GILD |
| FY2017 | −94.9 pp | GILD |
| FY2016 | −189.7 pp | GILD |
| FY2015 | −278.9 pp | GILD |
The higher net margin has changed hands between ARGX and GILD over this period.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ARGX's net margin has been more volatile than GILD's over the 10 comparable fiscal years — 111.0 percentage points of standard deviation against 14.2.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between ARGX and GILD over these 10 fiscal years — ARGX led in 2 and GILD in 8.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
GILD's return on equity has been more volatile than ARGX's over the 11 comparable fiscal years — 29.2 percentage points of standard deviation against 20.5.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between ARGX and GILD over these 11 fiscal years — ARGX led in 1 and GILD in 10.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.